MA1-10195

antibody from Invitrogen Antibodies

Targeting: EPCAM 17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1

Western blot (Recommended by provider)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunoprecipitation (Recommended by provider)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-10195

Provider

Invitrogen Antibodies

Product name

EpCAM Monoclonal Antibody (VU-1D9)

Antibody type

Monoclonal

Antigen

Other

Description

Immunohistochemistry (Paraffin): Antigen retrieval: heat (sodium citrate) + trypsin.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

VU-1D9

Vial size

100 µg

Concentration

1 mg/mL

Storage

4° C, do not freeze

References

Submitted references

Widespread GLI expression but limited canonical hedgehog signaling restricted to the ductular reaction in human chronic liver disease.

Grzelak CA, Sigglekow ND, Tirnitz-Parker JE, Hamson EJ, Warren A, Maneck B, Chen J, Patkunanathan B, Boland J, Cheng R, Shackel NA, Seth D, Bowen DG, Martelotto LG, Watkins DN, McCaughan GW
PloS one 2017;12(2):e0171480

---

Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells.

Kershaw S, Cummings J, Morris K, Tugwood J, Dive C
BMC cancer 2015 May 10;15:387

---

New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.

Becker TM, Caixeiro NJ, Lim SH, Tognela A, Kienzle N, Scott KF, Spring KJ, de Souza P
International journal of cancer 2014 Jun 1;134(11):2523-33

---

Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.

Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick-Silverman L, DiFeo A, Johnston D, Reynolds SR, Roses DF, Mosoian A
PloS one 2013;8(1):e55145

---

Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.

Bauerschlag D, Bräutigam K, Moll R, Sehouli J, Mustea A, Salehin D, Krajewska M, Reed JC, Maass N, Hampton GM, Meinhold-Heerlein I
Journal of cancer research and clinical oncology 2013 Feb;139(2):347-55

---

Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.

Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA
Cancer research 2013 Dec 1;73(23):7111-21

---

Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.

Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y
Annals of surgical oncology 2012 Jul;19 Suppl 3(Suppl 3):S634-45

---

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.

Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C
British journal of cancer 2012 Jan 31;106(3):508-16

---

Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.

Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N
Nature genetics 2009 Jan;41(1):112-7

---

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.

Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM
Oncogene 2005 Feb 3;24(6):1053-65

---

Gene expression patterns in ovarian carcinomas.

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI
Molecular biology of the cell 2003 Nov;14(11):4376-86

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of EpCAM was performed using HT-29 and HeLa cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 2% BSA for 1 hour at room temperature. The cells were labeled with EpCAM Mouse Monoclonal Antibody (Product # MA1-10195) at 1 µg/mL in 0.1% BSA and incubated overnight at 4 degree and then labeled with Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Product # A32723) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green) in HT-29 cells. Nuclei (Panel b: blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image of HT-29 cells, which is a positive model for EpCAM expression showing a plasma membrane localization. Panel e represents the merged image of HeLa cells, that are null for EpCAM protein expression. Panel f represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemistry staining of human prostate (paraffin sections) using anti-CD326 (VU-1D9) Monoclonal antibody (Product # MA1-10195).

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry surface staining pattern of MCF-7 cells stained using anti-human CD326 (VU-1D9) purified Monoclonal antibody (Product # MA1-10195) (concentration in sample 6 µg/mL) GAM APC.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Separation of MCF-7 cells (red-filled) from SP2 cells (black-dashed) in flow cytometry analysis (surface staining) of cell lines stained using anti-human CD326 (VU-1D9) purified Monoclonal antibody (Product # MA1-10195) (concentration in sample 6 µg/mL) GAM APC.